{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:11:23Z","timestamp":1789726283079,"version":"4.0.1"},"reference-count":9,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2017,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Failure to eradicate\n            <jats:named-content content-type=\"genus-species\">Helicobacter pylori<\/jats:named-content>\n            infection is often a result of antimicrobial resistance, which for clarithromycin is typically mediated by specific point mutations in the 23S rRNA gene. The purpose of this study was to define current patterns of antimicrobial susceptibility in\n            <jats:named-content content-type=\"genus-species\">H. pylori<\/jats:named-content>\n            isolates derived primarily from the United States and to survey them for the presence of point mutations in the 23S rRNA gene and assess the ability of these mutations to predict phenotypic clarithromycin susceptibility. Antimicrobial susceptibility testing was performed using agar dilution on 413\n            <jats:named-content content-type=\"genus-species\">H. pylori<\/jats:named-content>\n            isolates submitted to Mayo Medical Laboratories for susceptibility testing. For a subset of these isolates, a 150-bp segment of the 23S rRNA gene was sequenced. A total of 1,970 MICs were reported over the 4-year study period. The rate of clarithromycin resistance was high (70.4%), and elevated MICs were frequently observed for metronidazole (82.4% of isolates had an MIC of &gt;8 \u03bcg\/ml) and ciprofloxacin (53.5% of isolates had an MIC of &gt;1 \u03bcg\/ml). A total of 111 archived\n            <jats:named-content content-type=\"genus-species\">H. pylori<\/jats:named-content>\n            isolates underwent 23S rRNA gene sequencing; we found 95% concordance between genotypes and phenotypes (\n            <jats:italic>P<\/jats:italic>\n            = 0.9802). Resistance to clarithromycin was most commonly due to an A2143G mutation (82%), followed by A2142G (14%) and A2142C (4%) mutations. Clinical\n            <jats:named-content content-type=\"genus-species\">H. pylori<\/jats:named-content>\n            isolates derived primarily from the United States demonstrated a high rate of clarithromycin resistance and elevated metronidazole and ciprofloxacin MICs. The relative distribution of point mutations at positions 2143 and 2142 in the 23S rRNA gene in clarithromycin-resistant\n            <jats:named-content content-type=\"genus-species\">H. pylori<\/jats:named-content>\n            was similar to that reported from other parts of the world; these mutations predict phenotypic resistance to clarithromycin.\n          <\/jats:p>","DOI":"10.1128\/aac.02530-16","type":"journal-article","created":{"date-parts":[[2017,2,7]],"date-time":"2017-02-07T01:50:11Z","timestamp":1486432211000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":47,"title":["Phenotypic and Molecular Antimicrobial Susceptibility of Helicobacter pylori"],"prefix":"10.1128","volume":"61","author":[{"given":"Derrick","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, Wisconsin, USA"},{"name":"Division of Clinical Microbiology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Cunningham","sequence":"additional","affiliation":[{"name":"Division of Clinical Microbiology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolynn C.","family":"Cole","sequence":"additional","affiliation":[{"name":"Division of Clinical Microbiology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy C.","family":"Kohner","sequence":"additional","affiliation":[{"name":"Division of Clinical Microbiology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayawant N.","family":"Mandrekar","sequence":"additional","affiliation":[{"name":"Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6344-4141","authenticated-orcid":false,"given":"Robin","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Clinical Microbiology, Mayo Clinic, Rochester, Minnesota, USA"},{"name":"Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.563"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13497"},{"key":"e_1_3_1_4_2","volume-title":"Document M45","author":"Clinical and Laboratory Standards Institute","year":"2015","unstructured":"Clinical and Laboratory Standards Institute. 2015. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria\u20143rd ed. Document M45. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"3"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.161.9.1217"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2015.02.005"},{"key":"e_1_3_1_7_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing. 2016. Breakpoint tables for interpretation of MICs and zone diameters. Version 6.0. http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_7.0_Breakpoint_Tables.pdf."},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2003.022111"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000000380"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.03062-12"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02530-16","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02530-16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:52:14Z","timestamp":1645476734000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02530-16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["10.1128\/AAC.02530-16"],"URL":"https:\/\/doi.org\/10.1128\/aac.02530-16","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"2016-11-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-02-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-03-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02530-16"}}